Designated as an innovative company in the bio-health sector by the Korean Intellectual Property Office (KIPO)
Set to accelerate global medical aesthetics market expansion based on proprietary biomaterial technology

SEOUL, South Korea — USCAREPHARM, a company specializing in bio-medical aesthetics, announced that it has been selected for the "2026 2nd Innovative Premier 1000" initiative, a major government-backed policy program jointly led by 14 South Korean government ministries, including the Financial Services Commission.

The "Innovative Premier 1000" is a flagship national initiative designed to identify and intensively support small and medium-sized enterprises (SMEs) with outstanding innovativeness and high growth potential through cross-industry and financial collaboration.

USCAREPHARM was selected as an innovative enterprise following a rigorous evaluation by the Korean Intellectual Property Office (KIPO), which oversaw the bio-health sector selection process. Out of 547 companies chosen in this second round, KIPO selected only two companies in the bio-health category—underscoring USCAREPHARM’s exceptional intellectual property (IP) portfolio and technological innovation capabilities.

As an R&D-driven bio-health enterprise, USCAREPHARM has successfully established a robust R&D framework capable of transforming proprietary biomaterial technology into commercial products. The company has recently expanded its product portfolio under its flagship medical aesthetics brand, ERBELLA®, and is actively generating strong market momentum across Europe, Southeast Asia, and the Middle East.

Building on this selection, USCAREPHARM plans to leverage financial and strategic support from major policy financial institutions—including the Korea Development Bank (KDB), Industrial Bank of Korea (IBK), and the Export-Import Bank of Korea (KEXIM)—to accelerate its global expansion. The company aims to broaden its global footprint into markets such as Russia, the Philippines, and Mexico, while simultaneously strengthening its international medical device regulatory compliance framework.

"Selection for the Innovative Premier 1000 program carries significant meaning, as it validates USCAREPHARM’s technological prowess, intellectual property, and high potential for global growth," said a spokesperson for USCAREPHARM. "By strategically utilizing this government policy support, we will expedite our R&D, global regulatory approvals, production facility upgrades, and market expansion. Powered by our differentiated bio-health technology, we will continue to enhance product competitiveness and solidify our position as a trusted global leader in the medical aesthetics market."